^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
Published date:
02/13/2012
Excerpt:
A 62-year-old, non-smoking female with adenocarcinoma of the right lung...Her tumor cells had increased EGFR/HER1 copy number, as assessed by FISH...patient was treated with afatinib (50 mg/day). Within 2 weeks, the cervical soft-tissue swelling decreased with marked improvement in her general condition (ECOG PS: 1). On Day 15, a metabolic response was observed in a PET-CT scan.
DOI:
10.1016/j.lungcan.2012.01.008
